Cardiac biomarkers provide prognostic information in light-chain amyloidosis (AL). Recently a high sensitivity cardiac troponin T (hs-TnT) assay was developed that allows detection of minimal myocardial injury. We hypothesized that hs-TnT may improve risk stratification. Hs- 
Introduction
Light-chain amyloidosis (AL) is a plasma cell dyscrasia characterized by extracellular deposition of pathological insoluble beta-fibrillar immunoglobulin light-chains in diverse organs. Cardiac and renal involvement occurred in more than half of the patients diagnosed with AL. The extent of cardiac amyloidosis (CA) is the most important determinant of clinical outcome resulting in a median survival of about 6 months without therapy 1,2 . About two-thirds of the patients with CA die from sudden death or congestive heart failure within the first year after cardiac symptoms have been occurred 3, 4 . Moreover, CA may be considered one of the most therapeutically refractory forms of heart failure since medical treatment strategies for heart failure are neither effective nor well tolerated and patients are ineligible for treatment approaches that are capable to rapidly stop the production of the amyloidogenic light chains, e.g. high-dose melphalan chemotherapy and autologous stem cell support.
Due to the potential impact of cardiac involvement for the prognosis of systemic AL several parameters describing the cardiac morphology and function have been described for risk assessment 4, 5, [5] [6] [7] [8] . In addition, cardiac biomarkers, e.g. plasma levels of cardiac troponin T and N-terminal pro-brain natriuretic peptide (NT-proBNP), provided potent prognostic information in patients with AL [9] [10] [11] . Cardiac troponin T is a highly specific and sensitive marker of myocardial injury [12] [13] [14] , while NT-proBNP may be considered a sensitive indicator of cardiac overload.
Hitherto commercially available cardiac troponin assays (4 th generation) had a limit of detection of 0.01 µg/L with a recommended diagnostic threshold of 0.03 µg/L. Recently, improvements in the technology of cardiac troponin assays have allowed to provide fully automated assays with a limit of detection that is below the 99 th percentile of the 4 th generation troponin assays (3 ng/L) in a normal reference populations 15 with a recommended diagnostic threshold of 50 ng/L. Even minor elevations in patients with acute coronary syndrome are associated with an increased risk of an adverse outcome 16 and the use of the novel high-sensitivity troponin assays in patients with chest pain substantially improved the Thus, it is possible that even minor cardiac troponin elevations below the conventional limit of previous assays improve risk stratification in AL. Therefore, we retrospectively assessed a single measurement of plasma troponin T levels by the high-sensitivity assay (hs-TnT) in 163 patients newly diagnosed with AL to test the significance of the very low cardiac troponin T levels for risk assessment in patients with AL.
Methods
Between December 2005 and November 2008 163 patients (92 male, 71 female) were assessed at the Heidelberg Amyloidosis Center within 3 months after diagnosis of systemic AL. All patients included in the present analysis had biopsy-proven AL confirmed by Congo red staining and immunohistochemistry of any tissue specimen. In all patients plasma cell dyscrasia was documented by serum/urine immunofixation electrophoresis and serum free light-chain test (Binding Site GmbH, Schwetzingen, Germany).
Cardiac involvement was defined as an endomyocardial biopsy specimen containing amyloid (n=41) or by a history of congestive heart failure with myocardial wall thickening on cardiac ultrasound in the absence of arterial hypertension or valvular or coronary disease in a patients with extracardiac proven amyloidosis (n=61). Patients with extra-cardiac proven AL amyloidosis, but no definite exclusion as well as definite diagnosis of cardiac involvement by non-invasive methods were grouped as suspected cardiac involvement (n=24 . An additional plasma sample of each patient was frozen at −80°C until it was thawed and immediately used for the hs-TnT assay.
Approval for the study was obtained from the Medical University of Heidelberg institutional review board, conforming to the Declaration of Helsinki
24
. Informed consent forms were obtained from all patients prior to the investigation.
Quantification of cardiac biomarkers
Cardiac troponin T was measured using the 4 th generation assay and a novel high sensitivity assay (Roche Diagnostics, Mannheim, Germany) on an ELECSYS 2010 automated analyzer that uses chemiluminescence technology. The interassay coefficient of variation of the high sensitivity assay is 8% at 10 ng/L and 2.5% at 100 ng/L; the intraassay coefficient of variation is 5% at 10 ng/L and 1% at 100 ng/L. The diagnostic range of this assay is 3 to 10000 ng/L 25, 26 . The lower limit of detection for the 4 th generation assay is 0.01µg/L. The interassay coefficients of variation were 20% at 0.015µg/L, 10% at 0.03µg/L, and 5% at 0.08µg/L.
NTproBNP was measured using an electrochemiluminescence immunoassay (Elecsys proBNP, Roche Diagnostics, Mannheim, Germany). The measurement range extends from 5 to 35.000pg/ml. The minimal detectable concentration is 5pg/ml, and the coefficient of variation is 5.7% at 64pg/ml. 
Statistical analysis
Continuous data were expressed as mean±standard error of the mean (SEM). Categorical variables were expressed as absolute numbers and percentages. To test for significant differences between means, nonparametric Mann-Whitney U test or analysis of variance (ANOVA) with Newman-Keuls post test as appropriate after testing for normal distribution by the Kolmogorov-Smirnov test. Linear regression models were used to assess the influence of variables on hs-TnT. All tests were two-tailed and a p-value of less than 5% was regarded as statistically significant.
Receiver operating characteristics (ROC) curves for diagnosis of CA and all-cause mortality were used to assess the predictive accuracy of hs-TnT on the presence of CA and overall survival. Differences in overall survival, defined as the time between diagnosis and death from any cause, was assessed using log-rank analysis with right-censoring. Differences in overall survival were analysed using uni-and multivariable Cox-proportional hazard models and displayed by the Kaplan-Meier product limit method. In multivariate analyses, the main models were adjusted for variables that were associated with the clinical course of AL patients. A separate multivariate analysis excluding patients with markedly impaired renal function has been performed. Statistical analyses were performed using StatView (Version 5.0, SAS Institute, Cary, NC, USA).
Results

Patient Characteristics
The main characteristics of the 163 AL patients included in the study are shown in detail in TnT plasma level were lower than the detection limit of the hs-TnT (3 ng/L).
High-sensitivity cardiac troponin T and cardiac involvement
Troponin levels in blood show a consistent increase with amyloidosis. Even in the patients without evidence of CA by clinical indices the median hs-TnT levels were above the 99 th percentile of a normal reference population. In patients with suspected CA independent of further organ involvement mean hs-TnT plasma levels were significantly higher as compared to patients without CA, but lower than in patients with CA (figure 1). Highest levels were observed in patients with cardiac (and additional renal) involvement (figure 1). Mean plasma hs-TnT levels of patients with isolated renal involvement did not differ from patients with noncardiac organ involvement, but were significantly lower than in patients with predominant CA 
Discussion
Risk stratification of patients with AL amyloidosis (and cardiac involvement) is crucial. In the past multiple clinical indices have been reported to be useful as indicators of an adverse outcome such as electrocardiographic, echocardiographic, and laboratory parameters. In the present study the diagnostic and prognostic power of a novel troponin T assay with higher sensitivity and lower limit of detection was evaluated in 163 consecutive patients with AL amyloidosis. We observed that a single hs-TnT determination at the time of diagnosis provides important information on morphology and function, as well as even prognosis of patients with AL. These findings also point to the clinical significance of very low detectable levels of troponin release (beneath the detection limit of the currently available 4 th troponin T assay).
Cardiac troponin T has become the preferred markers for the diagnosis of acute myocardial infarction 27 as it correlates with acute myocardial infarction risk and with infarct size 28 .
Furthermore, even small elevations in patients with non ST-deviation acute coronary syndrome as measured by the 4 th generation troponin T assay are associated with an increased risk of an adverse outcome 16 . The use of a novel high-sensitivity cardiac troponin (I and T) assay increases the diagnostic accuracy and discrimination for the early diagnosis of myocardial infarction by a single measurement as compared with a conventional troponin T assay and other markers of myocardial necrosis 17, 18 . In patients with clinically stable coronary artery disease cardiac troponin T levels measured by the hs-TnT assay were elevated in 21% and significantly associated with the incidence of cardiovascular death and heart failure 29 .
These data were in line with reports from the ValHeft trial indicating a dose relationship of a single hs-TnT measurement with adverse outcome in patients with heart failure 30 . Here we show another clinical cause of non-ischemic troponin elvevation, namely AL amyloidosis.
Cardiac involvement was detected in more than half of the patients with AL. The extent of CA is the most important determinant of clinical outcome 1, 2 . Plasma troponin levels were associated with poor outcome of patients with AL amyloidosis 9, 10 . Therefore, it seems
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From plausible that cardiac troponin levels below the conventional limit of detection may indicate early cardiac involvement and may further discriminate between subjects at high risk and those at low risk for survival.
High-sensitivity troponin T and severity of cardiac amyloidosis
As some of the tools for diagnosis of CA require very much experience for early detection of cardiac involvement, assessment of the severity of CA by a single blood test offers a valuable benefit for clinicians. In the present study plasma troponin T levels determined by a novel assay with improved sensitivity and lower detection limit was strongly associated with the presence and severity of cardiac involvement. Due to the increased sensitivity 34 patients with troponin T lower than the detection limit had troponin T above the reference value of healthy reference population by the hs-TnT assay most likely indicating minor cardiac amyloid deposition. As demonstrated in the present study hs-TnT is associated in concentration dependent fashion with clinical, morphological, and functional state of the disease severity in a single parameter. Due to its wide measurement, the excellent reproducibility, and low costs, hs-TnT quantitation appears to be a valuable marker in the clinical routine for the evaluation of patients with AL amyloidosis. Since the extent of cardiac involvement is an adverse factor for autologous stem cell transplantation [34] [35] [36] , hs-TnT may aid in patient selection to avoid high treatment-related mortality 37 .
High-sensitivity troponin T and prognosis of patients with AL amyloidosis
Determining levels of circulating cardiac biomarkers has been demonstrated to be a powerful This emphasizes the impact of the use of the hs-TnT assay in patients with AL amyloidosis and indicates that in such highly selected and well characterized patients the hs-TnT method 
Limitations
Many of the AL patients were first referred to our Amyloidosis Center several months after their initial diagnoses. Thus, there might be a bias in the present patient cohort as indicated by a high rate of patients with cardiac involvement in previous studies 31 as well as the present study most likely due to the heart transplant program 40 or due to poor health with inability to visit our Amyloidosis Center. To avoid upward bias in the survival curves only patients with diagnosis within the last three months were included in the present study.
The best sensitivity and specificity according to the ROC-AUC analysis is low; however, with a decrease in the diagnostic cut-off by implementation of more sensitive and precise assay, sensitivity is further increased, but specificity is decreased owing to detection of more acute, subacute, and chronic cardiac diseases 29, 30 . However, a multitude of differential diagnoses of elevated troponin T levels are excluded in the present study by the pre-selection of patients with AL amyloidosis; thus, there is no need for a high specificity in contrast to the diagnosis of myocardial infarction when the troponin assay is used as a diagnostic criterion. Serial measurement of cardiac biomarkers for the response to chemotherapeutic treatment is of paramount interest for risk stratification as it has been demonstrated for ; however, the present study was to evaluate the prognostic value of a single measurement of hs-TnT as it has been demonstrated for patients with stable coronary artery disease 29 and stable heart failure 30 . The impact of serial measurement of hs-TnT for risk prediction needs to be addressed in future studies.
Conclusions
In conclusion, this is the first report on the use of a novel hs-TnT assay in a large cohort of patients with newly diagnosed AL amyloidosis. Our data show that plasma hs-TnT values in AL patients are invariably associated with the severity of cardiac involvement. Additionally, this high-sensitivity assay could provide useful information for clinicians, particularly for the improvement of risk stratification of AL patients according to the Mayo staging system as well as patients with insignificant troponin release, and probably may improve the early diagnosis of CA. Further studies are needed to evaluate hs-TnT plasma levels for monitoring the effect of treatment on cardiac involvement.
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